💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Vigabatrin

CHEMBL89598 Phase 4 Одобрено Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
129.2 g/mol
LogP
-2.2
Phase
4

This anticonvulsant medication is used to treat infantile spasms (a severe form of epilepsy in babies) and as an add-on treatment for complex partial seizures that have not responded to other medications. It works by blocking an enzyme that breaks down GABA, increasing levels of this inhibitory neurotransmitter in the brain. A serious and irreversible side effect is progressive narrowing of peripheral vision (visual field loss), which can occur in up to one-third of patients.

Молекулярная масса

129,1600 g/mol

LogP

-2,20

TPSA

63,30 Ų

Правило пяти Липинского

Соответствует

Терапевтические области

Glaucoma Epilepsy Non-Alcoholic Fatty Liver Disease Obesity Hypertension

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Структура

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
C=CC(N)CCC(=O)O

                

                

                
                

                    
InChI

                    
InChI=1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2,5H,1,3-4,7H2,(H,8,9)

                

                

                

                    
                    

                        
Molecular Formula

                        
C6H11NO2

                    

                    
                    

                        
HBD / HBA

                        
2 / 3

                    

                    
                    

                        
Вращаемые Связи

                        
4

                    

                    
                    
                    

                        
Тяжёлые Атомы

                        
9

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Часто задаваемые вопросы

                

                    
                    

                        
                        

                            
This anticonvulsant medication is used to treat infantile spasms (a severe form of epilepsy in babies) and as an add-on treatment for complex partial seizures that have not responded to other medications. It works by blocking an enzyme that breaks down GABA, increasing levels of this inhibitory neurotransmitter in the brain. A serious and irreversible side effect is progressive narrowing of peripheral vision (visual field loss), which can occur in up to one-third of patients.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Vigabatrin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL89598.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 5665.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Медицинский отказ от ответственности

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.